{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T02:38:24Z","timestamp":1790563104759,"version":"4.1.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,1,3]],"date-time":"2022-01-03T00:00:00Z","timestamp":1641168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,1,3]],"date-time":"2022-01-03T00:00:00Z","timestamp":1641168000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>This study aimed to investigate the effect of glucocorticoid doses on adverse pregnancy outcomes (APOs) in women complicated by systemic lupus erythematosus (SLE).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We investigated 74 pregnancies complicated by SLE or SLE-dominant mixed connective tissue disease. The pregnancies were managed from conception to delivery in our institution. We retrospectively evaluated whether the mean glucocorticoid dose during pregnancy is associated with APOs, including preterm birth (PB), low birth weight (LBW), and light-for-date (LFD). We also calculated the cut-off dose of glucocorticoid that affected APOs.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>All APOs occurred in 35 (50.7%) patients, with 14 cases of PB, 23 cases of LBW, and 10 cases of LFD. Patients with all APOs or PB had a higher dose of glucocorticoid during pregnancy than patients without all APOs or with full-term birth (<jats:italic>P<\/jats:italic>\u2009=\u20090.03, <jats:italic>P<\/jats:italic>\u2009&lt;\u2009\u00a00.01, respectively). Logistic regression analysis for all APOs and PB showed that the cut-off values of the mean glucocorticoid dose were 6.5 and 10.0\u2009mg\/day, respectively. Patients who delivered LBW or LFD newborns showed no significant difference in the glucocorticoid dose used during pregnancy than patients without LBW or LFD newborns. Patients who delivered LBW newborns were more likely to have used glucocorticoids during pregnancy (<jats:italic>P<\/jats:italic>\u00a0&lt;\u2009\u00a00.01).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>In pregnancies complicated by SLE, a relatively lower dose of glucocorticoid than previously reported is significantly related to APOs, especially PB. Therefore, the disease activity of patients with SLE should be managed with the appropriate lower dose of glucocorticoid during pregnancy.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13075-021-02699-1","type":"journal-article","created":{"date-parts":[[2022,1,3]],"date-time":"2022-01-03T07:03:20Z","timestamp":1641193400000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Preterm birth is strongly affected by the glucocorticoid dose during pregnancy in women complicated by systemic lupus erythematosus"],"prefix":"10.1186","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5792-9919","authenticated-orcid":false,"given":"Hiromi","family":"Shimada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Risa","family":"Wakiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Kanenishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuyuki","family":"Miyatake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shusaku","family":"Nakashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mai Mahmoud Fahmy","family":"Mansour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikiya","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taichi","family":"Miyagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Sugihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Ushio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rina","family":"Mino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mao","family":"Mizusaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Kameda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norimitsu","family":"Kadowaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Dobashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,3]]},"reference":[{"key":"2699_CR1","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1080\/14397595.2018.1452352","volume":"29","author":"A Ohyama","year":"2019","unstructured":"Ohyama A, Tsuboi H, Noma H, Terasaki M, Shimizu M, Toko H, et al. Associations between maternal clinical features and fetal outcomes in pregnancies of mothers with connective tissue diseases. Mod Rheumatol. 2019;29:344\u201350.","journal-title":"Mod Rheumatol"},{"key":"2699_CR2","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1177\/0961203319877258","volume":"28","author":"E Sugawara","year":"2019","unstructured":"Sugawara E, Kato M, Fujieda Y, Oku K, Bohgaki T, Yasuda S, et al. Pregnancy outcomes in women with rheumatic diseases: real-world observational study in Japan. Lupus. 2019;28:1407\u201316.","journal-title":"Lupus"},{"key":"2699_CR3","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1111\/1471-0528.16191","volume":"127","author":"H Kither","year":"2020","unstructured":"Kither H, Heazell A, Bruce IN, Tower C, Crocker I. Adverse pregnancy outcomes and subsequent development of connective tissue disease in the UK: an epidemiological study. BJOG. 2020;127:941\u20139.","journal-title":"BJOG"},{"key":"2699_CR4","first-page":"1","volume":"24","author":"S Tsuda","year":"2019","unstructured":"Tsuda S, Sameshima A, Sekine M, Kawaguchi H, Fujita D. Makino, et al. pre-conception status, obstetric outcome and use of medications during pregnancy of systemic lupus erythematosus (SLE), rheumatoid arthritis (RA) and inflammatory bowel disease (IBD) in Japan: multi-center retrospective descriptive study. Mod Rheumatol. 2019;24:1\u201310.","journal-title":"Mod Rheumatol"},{"key":"2699_CR5","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.ajog.2008.03.012","volume":"199","author":"ME Clowse","year":"2008","unstructured":"Clowse ME, Jamison M, Myers E, James AH. A national study of the complications of lupus in pregnancy. Am J Obstet Gynecol. 2008;199:127 e1\u20136.","journal-title":"Am J Obstet Gynecol"},{"key":"2699_CR6","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.jaut.2017.02.009","volume":"79","author":"PK Bundhun","year":"2017","unstructured":"Bundhun PK, Soogund MZ, Huang F. Impact of systemic lupus erythematosus on maternal and fetal outcomes following pregnancy: a meta-analysis of studies published between years 2001\u20132016. J Autoimmun. 2017;79:17\u201327.","journal-title":"J Autoimmun"},{"key":"2699_CR7","doi-asserted-by":"publisher","first-page":"153","DOI":"10.7326\/M14-2235","volume":"163","author":"JP Buyon","year":"2015","unstructured":"Buyon JP, Kim MY, Guerra MM, Laskin CA, Petri M, Lockshin MD, et al. Predictors of pregnancy outcomes in patients with lupus: a cohort study. Ann Intern Med. 2015;163:153\u201363.","journal-title":"Ann Intern Med"},{"key":"2699_CR8","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.jri.2017.11.005","volume":"125","author":"M Deguchi","year":"2018","unstructured":"Deguchi M, Maesawa Y, Kubota S, Morizane M, Tanimura K, Ebina Y, et al. Factors associated with adverse pregnancy outcomes in women with systemic lupus erythematosus. J Reprod Immunol. 2018;125:39\u201344.","journal-title":"J Reprod Immunol"},{"key":"2699_CR9","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.3899\/jrheum.100746","volume":"38","author":"ME Clowse","year":"2011","unstructured":"Clowse ME, Magder LS, Petri M. The clinical utility of measuring complement and anti-dsDNA antibodies during pregnancy in patients with systemic lupus erythematosus. J Rheumatol. 2011;38:1012\u20136.","journal-title":"J Rheumatol"},{"key":"2699_CR10","doi-asserted-by":"publisher","first-page":"e22843","DOI":"10.1097\/MD.0000000000022843","volume":"99","author":"H Shimada","year":"2020","unstructured":"Shimada H, Kaemda T, Kanenishi K, Miyatake N, Nakashima S, Wakiya R, et al. Factors affecting the Apgar score of offsprings born to mothers suffering from systemic lupus erythematosus. Medicine (Baltimore). 2020;99:e22843.","journal-title":"Medicine (Baltimore)"},{"key":"2699_CR11","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1002\/acr.24130","volume":"72","author":"LR Sammaritano","year":"2020","unstructured":"Sammaritano LR, Bermas BL, Chakravarty EE, Chambers C, Clowse MEB, Lockshin MD, et al. 2020 American College of Rheumatology guideline for the management of reproductive health in rheumatic and musculoskeletal diseases. Arthritis Care Res. 2020;72:461\u201388.","journal-title":"Arthritis Care Res"},{"key":"2699_CR12","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1093\/rheumatology\/kev404","volume":"55","author":"J Flint","year":"2016","unstructured":"Flint J, Panchal S, Hurrell A, van de Venne M, Gayed M, Schreiber K, et al. BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeeding-part I: standard and biologic disease modifying anti-rheumatic drugs and corticosteroids. Rheumatology (Oxford). 2016;55:1693\u20137.","journal-title":"Rheumatology (Oxford)"},{"key":"2699_CR13","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1136\/annrheumdis-2015-208840","volume":"75","author":"CG Skorpen","year":"2016","unstructured":"Skorpen CG, Hoelzenbein M, Tincani A, Fischer-Betz R, Elefant E, Chambers C, et al. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis. 2016;75:795\u2013810.","journal-title":"Ann Rheum Dis"},{"key":"2699_CR14","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.reprotox.2003.10.007","volume":"18","author":"C Gur","year":"2004","unstructured":"Gur C, Diav-Citrin O, Shechtman S, Arnon J, Ormoy A. Pregnancy outcome after first trimester exposure to corticosteroids: a prospective controlled study. Reprod Toxicol. 2004;18:93\u2013101.","journal-title":"Reprod Toxicol"},{"key":"2699_CR15","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.rdc.2017.04.013","volume":"43","author":"G Bandoli","year":"2017","unstructured":"Bandoli G, Palmsten K, Forbess Smith CJ, Chambers CD. A review of systemic corticosteroid use in pregnancy and the risk of select pregnancy and birth outcomes. Rheum Dis Clin N Am. 2017;43:489\u2013502.","journal-title":"Rheum Dis Clin N Am"},{"key":"2699_CR16","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1126\/science.705336","volume":"202","author":"JM Reinisch","year":"1978","unstructured":"Reinisch JM, Simon NG, Karow WG, Gandelman R. Prenatal exposure to prednisone in humans and animals retards intrauterine growth. Science. 1978;202:436\u20138.","journal-title":"Science"},{"key":"2699_CR17","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1111\/jog.12120","volume":"40","author":"A Shiozaki","year":"2014","unstructured":"Shiozaki A, Yoneda S, Nakabayashi M, Takeda Y, Takeda S, Sugimura M, et al. Multiple pregnancy, short cervix, part-time worker, steroid use, low educational level and male fetus are risk factors for preterm birth in Japan: a multicenter, prospective study. J Obstet Gynaecol Res. 2014;40:53\u201361.","journal-title":"J Obstet Gynaecol Res"},{"key":"2699_CR18","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1002\/pds.4410","volume":"27","author":"K Palmsten","year":"2018","unstructured":"Palmsten K, Rolland M, Heberrt MF, Clowse ME, Schatz M, Xu R, et al. Patterns of prednisone use during pregnancy in women with rheumatoid arthritis: daily and cumulative dose. Pharmacoepidemiol Drug Saf. 2018;27:430\u20138.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2699_CR19","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1007\/s10067-019-04450-3","volume":"38","author":"H Shimada","year":"2019","unstructured":"Shimada H, Kaemda T, Kanenishi K, Miyatake N, Nakashima S, Wakiya R, et al. Effect of biologic disease-modifying anti-rheumatic drugs for patients with rheumatoid arthritis who hope to become mothers. Clin Rheumatol. 2019;38:1453\u20138.","journal-title":"Clin Rheumatol"},{"key":"2699_CR20","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1016\/j.ajog.2005.02.063","volume":"192","author":"EF Charkravarty","year":"2005","unstructured":"Charkravarty EF, Colon I, Langen ES, Nix DA, El-Sayed YY, Genovese MC, et al. Factors that predict prematurity and preeclampsia in pregnancies that are complicated by systemic lupus erythematosus. Am J Obstet Gynecol. 2005;192:1897\u2013904.","journal-title":"Am J Obstet Gynecol"},{"key":"2699_CR21","doi-asserted-by":"publisher","first-page":"j895","DOI":"10.1136\/bmj.j895","volume":"356","author":"RJ Desai","year":"2017","unstructured":"Desai RJ, Bateman BT, Huybrechts KF, Patorno E, Hernandez-Diaz S, Park Y, et al. Risk of serious infections associated with use of immunosuppressive agents in pregnant women with autoimmune inflammatory conditions: cohort study. BMJ. 2017;356:j895.","journal-title":"BMJ"},{"key":"2699_CR22","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/j.coph.2013.03.004","volume":"13","author":"M \u00d8stensen","year":"2013","unstructured":"\u00d8stensen M, Forger F. How safe are anti-rheumatic drugs during pregnancy? Curr Opin Pharmacol. 2013;13:470\u20135.","journal-title":"Curr Opin Pharmacol"},{"key":"2699_CR23","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1586\/1744666X.2015.1033404","volume":"11","author":"C Ponticelli","year":"2015","unstructured":"Ponticelli C, Moroni G. Immunosuppression in pregnant women with systemic lupus erythematosus. Expert Rev Clin Immunol. 2015;11:549\u201352.","journal-title":"Expert Rev Clin Immunol"},{"key":"2699_CR24","doi-asserted-by":"publisher","first-page":"99","DOI":"10.3109\/03009740903449313","volume":"39","author":"K Mitchell","year":"2010","unstructured":"Mitchell K, Kaul M, Clowse ME. The management of rheumatic diseases in pregnancy. Scand J Rheumatol. 2010;39:99\u2013108.","journal-title":"Scand J Rheumatol"},{"key":"2699_CR25","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.jaip.2020.07.047","volume":"9","author":"K Palmsten","year":"2021","unstructured":"Palmsten K, Bandoli G, Watkins J, Vazquez-Benitez G, Gilmer TP, Chamber CD. Oral corticosteroids and risk of preterm birth in the California Medicaid. J Allergy Clin Immunol Pract. 2021;9:375\u201384 e5.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2699_CR26","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1002\/art.1780400928","volume":"40","author":"MC Hochberg","year":"1997","unstructured":"Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40:1725.","journal-title":"Arthritis Rheum"},{"key":"2699_CR27","first-page":"1","volume":"7","author":"Y Tanaka","year":"2019","unstructured":"Tanaka Y, Kuwana M, Fujii T, Kameda H, Muro Y, Fujio K, et al. Diagnostic criteria for mixed connective tissue disease (MCTD) from the Japan research committee of the ministry of health, labor, and welfare for systemic autoimmune diseases. Mod Rheumatol. 2019;7:1\u20135.","journal-title":"Mod Rheumatol"},{"key":"2699_CR28","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1002\/art.1780350606","volume":"35","author":"C Bombardier","year":"1992","unstructured":"Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI: a disease activity index for lupus patients. The committee on prognosis studies in SLE. Arthritis Rheum. 1992;35:630\u201340.","journal-title":"Arthritis Rheum"},{"key":"2699_CR29","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1016\/j.berh.2005.03.010","volume":"19","author":"B Griffiths","year":"2005","unstructured":"Griffiths B, Mosca M, Gordon C. Assessment of patients with systemic lupus erythematosus and the use of lupus disease activity indices. Best Pract Res Clin Rheumatol. 2005;19:658\u2013708.","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"9","key":"2699_CR30","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1136\/annrheumdis-2015-207726","volume":"75","author":"K Franklyn","year":"2016","unstructured":"Franklyn K, Lau CS, Navarra SV, Louthrenoo W, Latee A, Hamijoya L, et al. Definition and initial validation of a lupus low disease activity state (LLDAS). Ann Rheum Dis. 2016;75(9):1615\u201321.","journal-title":"Ann Rheum Dis"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-021-02699-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-021-02699-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-021-02699-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,3]],"date-time":"2022-01-03T19:14:39Z","timestamp":1641237279000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-021-02699-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,3]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2699"],"URL":"https:\/\/doi.org\/10.1186\/s13075-021-02699-1","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,3]]},"assertion":[{"value":"10 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"We did not obtain patients\u2019 informed consent or study approval because this was a retrospective, observational study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"10"}}